SCHEMBL909679

SCHEMBL909679

COCc1cc(OC)cc2c(=O)cc(-c3cccnc3)oc12

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CYP1A1 P04798 11/20 0.59
▸ CYP1B1 Q16678 11/20 0.59
▸ CYP1A2 P05177 10/20 0.59
▸ KDM4E B2RXH2 3/20 0.55
▸ KMT2A Q03164 2/20 0.55
▸ MEN1 O00255 1/20 0.55
▸ PPARG P37231 1/20 0.55
▸ PRKDC P78527 1/20 0.50
▸ LCK P06239 1/20 0.48
▸ ABCB1 P08183 1/20 0.43
▸ ABCG2 Q9UNQ0 1/20 0.43
▸ SIGMAR1 Q99720 1/20 0.42
▸ TNKS O95271 1/20 0.41
▸ CYP19A1 P11511 1/20 0.41
▸ TUBB4A P04350 1/20 0.41
▸ TUBB P07437 1/20 0.41
▸ TUBA3C P0DPH7 1/20 0.41
▸ TUBA1B P68363 1/20 0.41
▸ TUBA4A P68366 1/20 0.41
▸ TUBB4B P68371 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29589331 0.73 KDM4E (0.63) CYP1A1CYP1B1CYP1A2KDM4EKMT2A
SCHEMBL11558696 0.70 CYP1A1 (0.49) CYP1A1CYP1B1CYP1A2KDM4EKMT2A
SCHEMBL3696230 0.68 CYP1A1 (0.67) CYP1A1CYP1B1CYP1A2KDM4EKMT2A
SCHEMBL31632237 0.68 CYP1A1 (0.56) CYP1A1CYP1B1CYP1A2KDM4EKMT2A
SCHEMBL910340 0.68 CYP1A1 (0.54) CYP1A1CYP1B1CYP1A2KDM4EKMT2A
SCHEMBL11559459 0.67 CYP1A1 (0.47) CYP1A1CYP1B1CYP1A2KDM4EKMT2A
SCHEMBL12556193 0.67 TERT (0.71) CYP1A1CYP1B1CYP1A2KDM4EKMT2A
SCHEMBL31632465 0.67 CYP1A2 (0.65) CYP1A1CYP1B1CYP1A2KDM4EKMT2A
SCHEMBL31061509 0.67 CYP1A1 (1.00) CYP1A1CYP1B1CYP1A2KDM4EKMT2A
SCHEMBL1647031 0.67 TNKS (0.69) CYP1A1CYP1B1CYP1A2KDM4EKMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7872011-B2 Inhibition of phosphoinositide 3-kinase β ASTRAZENECA AB (SE) 2011-01-18 — — US disclosed
US-7598377-B2 (+-)-7-Methyl-2-morpholin-4-yl-9-(1-phenylaminoethyl)-pyrido[1,2-a]pyrimidin-4-one, for example; selective inhibitors of phosphoinositide (PI) 3-kinase beta for use in anti-thrombotic therapy ASTRAZENECA AB (SE) 2009-10-06 — — US disclosed
US-20080319021-A1 Inhibition Of Phosphoinositide 3-Kinase Beta KINACIA PTY. LTD. (AU) 2008-12-25 — — US disclosed
US-20060276470-A1 (+-)-7-Methyl-2-morpholin-4-yl-9-(1-phenylaminoethyl)-pyrido[1,2-a]pyrimidin-4-one, for example; selective inhibitors of phosphoinositide (PI) 3-kinase beta for use in anti-thrombotic therapy ASTRAZENECA AB (SE) 2006-12-07 — — US disclosed
EP-1537102-A1 INHIBITION OF PHSPHOINOSTIDE 3-DINASE BETA Kinacia Pty Ltd. (AU) 2005-06-08 — — EP disclosed
WO-2004016607-A1 INHIBITION OF PHOSPHOINOSITIDE 3-KINASE BETA KINACIA PTY LTD. (AU) 2004-02-26 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080319021-A1 Inhibition Of Phosphoinositide 3-Kinase Beta PI4KB, PI4KA, PI4K2B CYP1A1 4600/4885CYP1B1 3709/4885CYP1A2 4298/4885
US-20060276470-A1 (+-)-7-Methyl-2-morpholin-4-yl-9-(1-phenylaminoethyl)-pyrido[1,2-a]pyrimidin-4-one, for example; selective inhibitors of phosphoinositide (PI) 3-kinase beta for use in anti-thrombotic therapy PI4KA, PI4KB, PI4K2B CYP1A1 3424/4885CYP1B1 1653/4885CYP1A2 3026/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback